TheStreet.com Speaks – Evaluating Pharma Stock Before Approvals – A Talk with Adam Feuerstein

A few weeks ago, I noticed an excellent article by Adam Feuerstein, Senior Columnist at TheStreet.com called Putting a Value on Provenge  describing what went into the evaluation of a single biotech company when analyzing the impact of an approval on stock price.  I found it extremely interesting to look at all the variables that are involved.

I asked Adam if he would be interested in chatting about that in a podcast and he kindly agreed.

We covered the objective and subjective factors that go into looking at a company as a new product is coming out.  We also discussed some of the factors that lead to a stock price that goes up after an announcement of an approvable letter versus one that tanks.  And he shared thoughts on challenges for the coming year.

I hope you enjoy and many thanks to Adam Feuerstein at TheStreet.com

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
This entry was posted in Podcast. Bookmark the permalink.

One Response to TheStreet.com Speaks – Evaluating Pharma Stock Before Approvals – A Talk with Adam Feuerstein

  1. Peter Vandenberg says:

    I am looking for the fall will be a very busy time for U.S. drug approvals 21 drugs facing FDA approval decisions. I saw your ariticle today at 08:2i AM EDT.CAN YOU SEND IT TO ME ? Thanks